Skip to main content

Research Repository

Advanced Search

Novel inhibitors of AChE and Aβ aggregation with neuroprotective properties as lead compounds for the treatment of Alzheimer's disease

Liu, Yulin; Uras, Giuseppe; Onuwaje, Itse; Li, Wenlong; Yao, Hong; Xu, Shengtao; Li, Xinuo; Li, Xinnan; Phillips, James; Allen, Stephanie; Gong, Qi; Zhang, Haiyan; Zhu, Zheying; Liu, Jie; Xu, Jinyi

Novel inhibitors of AChE and Aβ aggregation with neuroprotective properties as lead compounds for the treatment of Alzheimer's disease Thumbnail


Authors

Yulin Liu

Giuseppe Uras

Itse Onuwaje

Wenlong Li

Hong Yao

Shengtao Xu

Xinuo Li

Xinnan Li

James Phillips

Stephanie Allen

Qi Gong

Haiyan Zhang

Dr ZHEYING ZHU Zheying.Zhu@nottingham.ac.uk
ASSOCIATE PROFESSOR IN INTERNATIONAL PHARMACY AND TRADITIONAL MEDICINES

Jie Liu

Jinyi Xu



Abstract

A series of sulfone analogs of donepezil were designed and synthesized as novel acetylcholinesterase (AChE) inhibitors with the potent inhibiting Aβ aggregation and providing neuroprotective effects as potential modalities for Alzheimer's disease (AD). Most of the target compounds displayed effective inhibition of AChE, especially compound 24r which displayed powerful inhibitory activity (IC50 = 2.4 nM). Kinetic and docking studies indicated that compound 24r was a mixed-type inhibitor. Furthermore, in glyceraldehyde (GA)-exposed SH-SY5Y differentiated neuronal cells, compound 24r could potently inhibit AChE, reduce tau phosphorylation at S396 residue, provide neuroprotection by rescuing neuronal morphology and increasing cell viability. It was also found to reduce amyloid aggregation in the presence of AChE. In addition, compound 24r showed evident protections from mitochondrial membrane dysfunction and oxidative stress in okadaic acid-induced pharmacological models. Moreover, compound 24r exhibited more effective treatment prospects in vivo than donepezil, including a moderate blood-brain barrier permeability, a more potent AChE inhibitory activity and behavioral improvement in scopolamine-induced cognition-impaired mice model at a much lower dose. Collectively, compound 24r is a promising lead compound for further investigation to discovery and development of new anti-AD agents.

Citation

Liu, Y., Uras, G., Onuwaje, I., Li, W., Yao, H., Xu, S., Li, X., Li, X., Phillips, J., Allen, S., Gong, Q., Zhang, H., Zhu, Z., Liu, J., & Xu, J. (2022). Novel inhibitors of AChE and Aβ aggregation with neuroprotective properties as lead compounds for the treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 235, Article 114305. https://doi.org/10.1016/j.ejmech.2022.114305

Journal Article Type Article
Acceptance Date Mar 16, 2022
Online Publication Date Mar 24, 2022
Publication Date May 5, 2022
Deposit Date Apr 5, 2022
Publicly Available Date Mar 25, 2023
Journal European Journal of Medicinal Chemistry
Print ISSN 0223-5234
Electronic ISSN 1768-3254
Publisher Elsevier
Peer Reviewed Peer Reviewed
Volume 235
Article Number 114305
DOI https://doi.org/10.1016/j.ejmech.2022.114305
Keywords Organic Chemistry; Drug Discovery; Pharmacology; General Medicine
Public URL https://nottingham-repository.worktribe.com/output/7709148
Publisher URL https://www.sciencedirect.com/science/article/pii/S0223523422002070?via%3Dihub

Files





You might also like



Downloadable Citations